Literature DB >> 8740586

Computer-assisted microscope characterization of BCNU-induced modifications in the collective behavior of 12 human brain cancer cell lines.

I Camby1, I Salmon, A Danguy, J L Pasteels, R Kiss.   

Abstract

The aim of our study is to characterize the disturbance induced by repeated BCNU treatments in 12 human brain tumor cell lines in terms of their collective behavior. This collective behavior was characterized by means of the Delaunay triangulation and Voronoi mathematical paving techniques combined with the computer-assisted microscope analysis of Feulgen-stained nuclei. This methodology enabled growth to be characterized in terms of cell colony size and density. In addition to this colony pattern characterization, the DNA ploidy level was assessed by means of DNA histogram typing. The cell proliferation level was also determined. Ten astrocytic and two medulloblastoma cell lines treated weekly with BCNU were analyzed. Study of the cell colony architecture and cell proliferation revealed specific BCNU-induced modifications in connection with the origins of the cell lines, i.e. astrocytoma (AST), glioblastoma (GBM), or medulloblastoma (MED). The BCNU-induced effect on GBM (the more malignant of the cell lines) was very different in that proliferation was weakened, but the cell colony density increased after a latency phase. The decrease in cell colony density and cell proliferation of MED seems to indicate that they are more sensitive to BCNU than GBM, but relatively tolerant of this type of chemotherapy in comparison with AST.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740586     DOI: 10.1007/bf00300441

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  40 in total

1.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.

Authors:  L R Livingstone; A White; J Sprouse; E Livanos; T Jacks; T D Tlsty
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

2.  Long term culture of normal and neoplastic human glia.

Authors:  J Pontén; E H Macintyre
Journal:  Acta Pathol Microbiol Scand       Date:  1968

3.  Computer-assisted microscope analysis of morphonuclear modifications induced by anticancer antimetabolites in cell lines cultured in vitro.

Authors:  O Pauwels; R Kiss; G Atassi
Journal:  Anticancer Drugs       Date:  1994-04       Impact factor: 2.248

4.  Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate.

Authors:  B E Miller; F R Miller; G H Heppner
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

Review 5.  Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa.

Authors:  R J Packer
Journal:  Ann Neurol       Date:  1990-12       Impact factor: 10.422

6.  Influence of culture media on the morphological differentiation of the PC-3 and DU145 prostatic neoplastic cell lines.

Authors:  I Camby; C Etievant; M Petein; R Dedecker; R van Velthoven; A Danguy; J L Pasteels; R Kiss
Journal:  Prostate       Date:  1994-04       Impact factor: 4.104

7.  Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer.

Authors:  P Carder; A H Wyllie; C A Purdie; R G Morris; S White; J Piris; C C Bird
Journal:  Oncogene       Date:  1993-05       Impact factor: 9.867

8.  Hyperthermic potentiation of BCNU toxicity in BCNU-resistant human glioma cells.

Authors:  V F Da Silva; M Feeley; G P Raaphorst
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

9.  Characterization of the differentiation of human colorectal cancer cell lines by means of Voronoi diagrams.

Authors:  F Darro; A Kruczynski; C Etievant; J Martinez; J L Pasteels; R Kiss
Journal:  Cytometry       Date:  1993-10

10.  p53 protein in low-grade astrocytomas: a study with long-term follow-up.

Authors:  P Iuzzolino; C Ghimenton; A Nicolato; F Giorgiutti; P Fina; C Doglioni; M Barbareschi
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.